US Stock Insider Trading | MiNK Therapeutics disclosed four insider transactions on March 11

K-LinePoet · 2026-04-05T16:57:21+00:00

MiNK Therapeutics disclosed recent insider trading activity by Director Ryan Barbara on March 11, 2026. He sold 1,300 shares on March 10, and company executives and directors have also conducted multiple transactions in recent months. MiNK is a biopharmaceutical company focused on developing iNKT cell therapies.

K-LinePoet

2026-04-05 16:57:21

Abstract generation in progress

On March 11, 2026, MiNK Therapeutics (INKT) disclosed four transactions by company insiders. Director Ryan Barbara sold 500 shares on March 10, 2026.

【Recent Insider Transactions】

Disclosure Date	Title	Name	Transaction Date	Buy/Sell	Quantity	Trade Price/US$	Total Amount/US$
March 11, 2026	Director	Ryan Barbara	March 10, 2026	Sell	300	15.28	4584.66
March 11, 2026	Director	Ryan Barbara	March 10, 2026	Sell	500	15.30	7650.00
March 11, 2026	Director	Ryan Barbara	March 10, 2026	Sell	500	15.57	7782.60
March 11, 2026	Director	Ryan Barbara	March 9, 2026	Sell	200	10.17	2034.50
January 14, 2026	Executive Officer	Buell Jennifer	January 2, 2026	Sell	10k	11.12	111.5k
January 6, 2026	Executive Officer	Buell Jennifer	January 2, 2026	Buy	31.5k	11.12	350k
December 3, 2025	Director	Behner Peter、Corvese Brian、Holcomb John Bradley、Kadlec Robert Peter、Ryan Barbara、WIINBERG ULF	December 1, 2025	Buy	8288	11.09	91.9k
September 11, 2025	Executive Officer	Buell Jennifer	September 9, 2025	Buy	18.2k	15.36	280k
September 3, 2025	Director	Behner Peter、Corvese Brian、Kadlec Robert Peter、Ryan Barbara、WIINBERG ULF	September 2, 2025	Buy	5730	13.86	79.4k
June 4, 2025	Director	Behner Peter、Corvese Brian、Kadlec Robert Peter、Ryan Barbara、WIINBERG ULF	June 2, 2025	Buy	11.1k	7.17	79.4k

【Company Information】

MiNK Therapeutics, Inc. was incorporated in Delaware in July 2017. The company is a clinical-stage biopharmaceutical company that is pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf iNKT cell therapies to treat cancer and other immune-mediated diseases. The company is developing a wholly owned or exclusively licensed natural and engineered iNKT cell pipeline using its platform and manufacturing capabilities, and expects to provide multiple clinical and preclinical readouts in 2021 and 2022. The company’s strategy is to advance an accessible, scalable, and effective cell therapy platform, leveraging the innate and durable biological advantages of iNKT cells to optimize scalability and support rapid clinical development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes